Expanding Lung Cancer Screening to Never-Smokers: Promising Developments

Recent findings suggest that lung cancer screening via low-dose computed tomography (LDCT) could be beneficial for individuals who have never smoked, a group for which lung cancer incidence is increasing. While LDCT screening is already established as a way to reduce mortality in high-risk smokers, its application to never-smokers remains under investigation. Lung cancer in never-smokers is estimated to be the fifth leading cause of cancer-related deaths worldwide, with particularly high rates in Asia due to genetic factors such as EGFR mutations.

A key study, the Chinese Lung-Care Project presented at the European Lung Cancer Congress (ELCC) 2026, reports promising results. This study followed nearly 12,000 individuals aged 40-74 over seven years, revealing a 55% reduction in lung cancer mortality through screening compared to a non-screened group. Particularly noteworthy is the 72% reduction in deaths observed among women. Screen-detected cases showed significantly improved survival rates (hazard ratio 0.13; 95% CI, 0.09-0.19; p<0.001), with 81.5% of cancers diagnosed at stage 1, a stark contrast to the 25.1% in the non-screening group.

These findings align with evidence from other studies. The Taiwanese TALENT study found a 2.6% lung cancer diagnosis rate after LDCT screening among never-smokers. Similarly, preliminary results from the U.S. FANSS study suggest LDCT screening is feasible and effective in female Asian non-smokers, revealing a 1.5% incidence of detectable lung adenocarcinoma.

While these findings are promising, several challenges must be addressed before widespread implementation. The financial and logistical burdens of LDCT programs, along with concerns over false positives leading to unnecessary procedures, are significant hurdles. Development of nodule-management strategies is crucial to improve diagnostic accuracy and reduce invasive follow-up. Additionally, education and support could mitigate reluctance among potential screening candidates.

Refinement of screening criteria is needed, leveraging existing data to identify biomarkers for better targeting non-smokers at risk. As targeted therapies for early-stage lung cancer become more available, overcoming these challenges remains vital to curb the growing impact of lung cancer in never-smokers. Further studies and long-term follow-up will be essential in confirming and expanding upon the potential benefits observed thus far.